These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
116 related articles for article (PubMed ID: 17255582)
21. Novartis challenges India's drug patent laws in Supreme Court. Billingsley M BMJ; 2012 Feb; 344():e1279. PubMed ID: 22354594 [No Abstract] [Full Text] [Related]
22. MSF challenges pneumococcal vaccine patent in India. Usher AD Lancet Infect Dis; 2018 Mar; 18(3):254-255. PubMed ID: 29428402 [No Abstract] [Full Text] [Related]
23. Indian patients go to court over cancer drug. Murdur G BMJ; 2004 Aug; 329(7463):419. PubMed ID: 15321889 [No Abstract] [Full Text] [Related]
24. Final hearings begin in epic legal battle over Novartis drug in India. Mudur G BMJ; 2012 Sep; 345():e6257. PubMed ID: 22991008 [No Abstract] [Full Text] [Related]
25. India's decision on Gleevec: implications for the future. Wilensky GR Healthc Financ Manage; 2013 May; 67(5):32-3. PubMed ID: 23678685 [No Abstract] [Full Text] [Related]
26. Changes to India's patent law may deny cheap drugs to millions. Mudur G BMJ; 2005 Mar; 330(7493):692. PubMed ID: 15790640 [No Abstract] [Full Text] [Related]
27. Patent litigation in India continues to throw up new challenges. Reddy Thikkavarapu P Pharm Pat Anal; 2016 Jul; 5(4):211-6. PubMed ID: 27348790 [TBL] [Abstract][Full Text] [Related]
28. India: multi-national pharmaceutical company challenges patent law. Betteridge G HIV AIDS Policy Law Rev; 2007 May; 12(1):35, 38. PubMed ID: 17715534 [No Abstract] [Full Text] [Related]
29. Indian biogenerics industry emerges. Jayaraman KS Nat Biotechnol; 2003 Oct; 21(10):1115-6. PubMed ID: 14520378 [No Abstract] [Full Text] [Related]
30. Legal challenge to India's patent laws threatens access to generic drugs, says charity. Moszynski P BMJ; 2011 Sep; 343():d5753. PubMed ID: 21908529 [No Abstract] [Full Text] [Related]
31. Novartis faces growing pressure to drop patent case against Indian government. Hargreaves S BMJ; 2007 Feb; 334(7590):383. PubMed ID: 17322224 [No Abstract] [Full Text] [Related]
32. India's patent ecosystem - encouraging strong patents or discouraging innovation? Harrison C Nat Rev Drug Discov; 2013 Oct; 12(10):732-3. PubMed ID: 24080690 [No Abstract] [Full Text] [Related]
33. Indian generic drug production. Benefits of EU-India free trade agreement. Ager B BMJ; 2011 Apr; 342():d2439. PubMed ID: 21502277 [No Abstract] [Full Text] [Related]
34. Patent. Battle lines are drawn over generic AIDS drug. AIDS Policy Law; 2005 Aug; 20(16):6. PubMed ID: 16161208 [No Abstract] [Full Text] [Related]
35. Intellectual property. Balancing innovation and access: patent challenges tip the scales. Higgins MJ; Graham SJ Science; 2009 Oct; 326(5951):370-1. PubMed ID: 19833944 [No Abstract] [Full Text] [Related]
36. Herbal drug patenting in India: IP potential. Sahoo N; Manchikanti P; Dey SH J Ethnopharmacol; 2011 Sep; 137(1):289-97. PubMed ID: 21640810 [TBL] [Abstract][Full Text] [Related]
38. Indian pharmaceutical patent prosecution: The changing role of Section 3(d). Sampat BN; Shadlen KC PLoS One; 2018; 13(4):e0194714. PubMed ID: 29608604 [TBL] [Abstract][Full Text] [Related]
39. Drug resistance, patent resistance: Indian pharmaceuticals and the impact of a new patent regime. Halliburton M Glob Public Health; 2009; 4(6):515-27. PubMed ID: 19548158 [TBL] [Abstract][Full Text] [Related]
40. Litgation over for AstraZeneca’s Crestor® drug. Sklan A Pharm Pat Anal; 2013 May; 2(3):301. PubMed ID: 24386659 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]